Navigation
Pages
Welcome to ScanBalt Business
Today's Portrait Highlights
Metis Baltic R & D and Innovation Management
Metis Baltic is a Research and Technological Development management company with extensive experience in research project proposal preparation; consultation regarding RTD funding sources; intellectual property management; commercialisation of research results. Metis Baltic offers wide spectrum assistance for researchers from universities, research centres and private organisations in preparation of European Commission’s 7th Framework Programme proposals, and well as proposals for Competitiveness and Innovation Framework Programme, EUREKA, EUROSTARS, and Structural funds in all research areas.
Visit WebsiteIVEX Lab
IVEX Lab helps investigators in their efforts to find safer and more effective treatments for major diseases, including cancer. Focusing to preclinical drug efficacy studies, our team can develop novel tools that meet your experimental needs, ranging from molecular cloning and stable expression to in vivo xenograft studies. IVEX Lab is CRO with highly experienced personnel as well as relevant technical infrastructure. We have implemented live animal imaging methodology that enables to perform experiments with high sensitivity, accuracy and speed, at the same time reducing animal numbers.
Visit WebsiteDelSiTech Ltd
DelSiTech is an innovative Finnish drug delivery technology company that helps its customers to turn their active agents into novel and commercially viable therapeutic drug products. DelSiTech offers one-stop shop opportunity in drug delivery up to early clinical proof of concept. The Company’s proprietary drug delivery technology is based on biodegradable silica (SiO2) matrix into which the active ingredient is embedded. The matrix can be designed to biodegrade at the required rate to assure a tightly controlled release of the active substance, providing a better therapeutic effect in situ and causing lower systemic and local adverse effects than alternative delivery systems. DelSiTech also develops its own supergeneric drug products to address significant unmet medical and commercial needs. The lead product, 1308 is a long-acting subcutaneous depot injection that offers for the first time a patient-friendly slow release treatment option to chronic hepatitis B infection.
Visit Website